Systematic Review of the Current Status of Human Sarcoma Cell Lines

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2018) P G Casali et al.   ANNALS OF ONCOLOGY

Patient-derived xenograft models in musculoskeletal malignancies

(2018) Wan Lu et al.   Journal of Translational Medicine

Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis

(2018) Clara Benna et al.   Oncotarget

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2018) P G Casali et al.   ANNALS OF ONCOLOGY

Germline Mutations in Cancer Predisposition Genes are Frequent in Sporadic Sarcomas

(2017) Sock Hoai Chan et al.   Scientific Reports

Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone

(2016) Frank Traub et al.   EUROPEAN JOURNAL OF CANCER

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

(2016) Patrick Schöffski et al.   LANCET

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

(2016) William D Tap et al.   LANCET

Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial

(2016) Sophie Piperno-Neumann et al.   LANCET ONCOLOGY

Monogenic and polygenic determinants of sarcoma risk: an international genetic study

(2016) Mandy L Ballinger et al.   LANCET ONCOLOGY

Sarcomas Associated With Genetic Cancer Predisposition Syndromes: A Review

(2016) M. Farid et al.   ONCOLOGIST

Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors

(2016) Tetsuro Yamagishi et al.   PLoS One

Refinements in Sarcoma Classification in the Current 2013 World Health Organization Classification of Tumours of Soft Tissue and Bone

(2016) Vickie Y. Jo et al.   Surgical Oncology Clinics of North America

Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP)

(2015) S. Stacchiotti et al.   CLINICAL CANCER RESEARCH

Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group

(2015) Axel Le Cesne et al.   EUROPEAN JOURNAL OF CANCER

Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression

(2015) B. A. Teicher et al.   MOLECULAR CANCER THERAPEUTICS

Germline Mutations in Predisposition Genes in Pediatric Cancer

(2015) Jinghui Zhang et al.   NEW ENGLAND JOURNAL OF MEDICINE

RANKL blockade prevents and treats aggressive osteosarcomas

(2015) Yan Chen et al.   Science Translational Medicine

Patient-derived bladder cancer xenografts: a systematic review

(2015) Carina Bernardo et al.   Translational Research

Germline PTPRD Mutations in Ewing Sarcoma: Biologic and Clinical Implications

(2015) Yunyun Jiang et al.   Oncotarget

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

(2014) T Yoshida et al.   BRITISH JOURNAL OF CANCER

Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

(2014) Yasuhiro Funahashi et al.   CANCER SCIENCE

Molecular diagnosis of soft tissue neoplasia: clinical applications and recent advances

(2014) Meera Hameed   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

(2014) Adam S. Crystal et al.   SCIENCE

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program

(2013) Jean-Yves Blay et al.   BMC CANCER

Evaluating cell lines as tumour models by comparison of genomic profiles

(2013) Silvia Domcke et al.   Nature Communications

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor

(2010) P. Hamberg et al.   ONCOLOGIST

Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors

(2010) Katherine W. Eaton et al.   PEDIATRIC BLOOD & CANCER

Phase I Trial of Pazopanib in Patients with Advanced Cancer

(2009) H. I. Hurwitz et al.   CLINICAL CANCER RESEARCH

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

(2009) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

(2009) Ronald P DeMatteo et al.   LANCET

Molecular pathology of sarcomas: concepts and clinical implications

(2009) Judith V. M. G. Bovée et al.   VIRCHOWS ARCHIV

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY